Glofitamab in Patients with relapsed/refractory (R/R) diffuse large B-Cell Lymphoma (DLBCL) and ≥2 prior Lines of Therapy: Key Results of the Phase-II Expansion

被引：0
|
作者：
Hutchings, M. [1 ]
Dickinson, M. [2 ,3 ]
Carlo-Stella, C. [4 ,5 ]
Morschhauser, F. [6 ,7 ]
Bachy, E. [8 ]
Corradini, P. [9 ,10 ]
Iacoboni, G. [11 ]
Khan, C. [12 ]
Wrobel, T. [13 ]
Offner, F. [14 ]
Trneny, M. [15 ]
Wu, S. -J. [16 ]
Cartron, G. [17 ]
Hertzberg, M. [18 ,19 ]
Sureda, A. [20 ]
Perez-Callejo, D. [21 ]
Lundberg, L. [21 ]
Relf, J. [22 ]
Clark, E. [22 ]
Humphrey, K. [21 ]
机构：
[1] Rigshosp, Copenhagen, Denmark
[2] Royal Melbourne Hosp, Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[3] Univ Melbourne, Melbourne, Vic, Australia
[4] Humanitas Univ, Milan, Italy
[5] IRCCS Humanitas Res Hosp, Milan, Italy
[6] Hop Claude Huriez, Lille, France
[7] CHU Lille, Lille, France
[8] Ctr Hosp Lyon Sud, Lyon, France
[9] Univ Milan, Milan, Italy
[10] Ist Nazl Tumori, Fdn Ist Ricovero & Cura Carattere Sci IRCCS, Milan, Italy
[11] Vall Hebron Univ Hosp, Barcelona, Spain
[12] Allegheny Hlth Network, Pittsburgh, PA USA
[13] Univ Med Wroclaw, Wroclaw, Poland
[14] Univ Ziekenhuis Gent, Ghent, Belgium
[15] Charles Univ Hosp, Prague, Czech Republic
[16] Natl Taiwan Univ Hosp, Taipei, Taiwan
[17] CHU Montpellier, Montpellier, France
[18] Prince Wales Hosp, Sydney, NSW, Australia
[19] Univ New South Wales, Sydney, NSW, Australia
[20] Inst Catala Oncol Hosp, Barcelona, Spain
[21] F Hoffmann Roche Ltd, Basel, Switzerland
[22] Roche Prod Ltd, Welwyn Garden City, England
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2022年 / 45卷 / SUPPL 2期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V190
引用
收藏
页码：50 / 51
页数：2
相关论文
共 50 条
  • [1] Glofitamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and ≥ 2 prior therapies: Pivotal phase II expansion results.
    Dickinson, Michael
    Carlo-Stella, Carmelo
    Morschhauser, Franck
    Bachy, Emmanuel
    Corradini, Paolo
    Iacoboni, Gloria
    Khan, Cyrus
    Wrobel, Tomasz
    Offner, Fritz
    Trneny, Marek
    Wu, Shang-Ju
    Cartron, Guillaume
    Hertzberg, Mark
    Balari, Anna Sureda
    Perez-Callejo, David
    Lundberg, Linda
    Relf, James
    Clark, Emma
    Humphrey, Kathryn
    Hutchings, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [2] Glofitamab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma and ≥2 Prior Therapies: Results From a Pivotal Phase II Expansion Study
    Dickinson, Michael
    Carlo-Stella, Carmelo
    Morschhauser, Franck
    Bachy, Emmanuel
    Corradini, Paolo
    Iacoboni, Gloria
    Khan, Cyrus
    Wrobel, Thomasz
    Offner, Fritz
    Trneny, Marek
    Wu, Shang-Ju
    Cartron, Guillaume
    Hertzberg, Mark
    Sureda, Anna
    Perez-Callejo, David
    Lundberg, Linda
    Relf, James
    Clark, Emma
    Humphrey, Kathryn
    Hutchings, Martin
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S435 - S435
  • [3] Glofitamab in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma and ≥2 Prior Therapies: Results from a Pivotal Phase II Expansion Study
    Michael, Dickinson
    Carmelo, Carlo-Stella
    Franck, Morschhauser
    Emmanuel, Bachy
    Paolo, Corradini
    Gloria, Iacoboni
    Cyrus, Khan
    Tomasz, Wrobel
    Fritz, Offner
    Marek, Trneny
    Shang-Ju, Wu
    Guillaume, Cartron
    Mark, Hertzberg
    Anna, Sureda
    David, Perez-Callejo
    Linda, Lundberg
    James, Relf
    Emma, Clark
    Kathryn, Humphrey
    Martin, Hutchings
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : S39 - S40
  • [4] A Phase 2b Study of Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
    Kalakonda, Nagesh
    Cavallo, Federica
    Follows, George
    Goy, Andre
    Vermaat, Joost S. P.
    Casasnovas, Olivier
    Lavee, Orly
    Maerevoet, Marie
    Zijlstra, Josee
    Bakhshi, Sameer
    Bouabdallah, Reda
    Choquet, Sylvain
    Gurion, Ronit
    Hill, Brian
    Jaeger, Ulrich
    Sancho, Juan-Manuel
    Schuster, Michael
    Thieblemont, Catherine
    De la Cruz, Fatima
    Egyed, Miklos
    Mishra, Sourav
    Offner, Fritz
    Vassilakopoulos, Theodoros
    Warzocha, Krzysztof
    McCarthy, Daniel
    Ma, Xiwen
    Corona, Kelly
    Saint-Martin, Jean-Richard
    Joshi, Anita
    Shah, Jatin
    Van den Neste, Eric
    Canales, Miguel
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S248 - S249
  • [5] Acalabrutinib monotherapy in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
    Dyer, Martin J. S.
    De Vos, Sven
    Ruan, Jia
    Flowers, Christopher
    Maddocks, Kami J.
    Rule, Simon
    Hamdy, Ahmed M.
    Izumi, Raquel
    Slatter, J. Greg
    Cheung, Jean
    Frigualt, Melanie M.
    Wei, Helen
    Mourya, Sanchita
    Hunder, Naomi N. H.
    Fowler, Nathan Hale
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [6] Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Dickinson, Michael J.
    Carlo-Stella, Carmelo
    Morschhauser, Franck
    Bachy, Emmanuel
    Corradini, Paolo
    Iacoboni, Gloria
    Khan, Cyrus
    Wrobel, Tomasz
    Offner, Fritz
    Wu, Shang-Ju
    Cartron, Guillaume
    Hertzberg, Mark
    Sureda, Anna
    Perez-Callejo, David
    Lundberg, Linda
    Relf, James
    Dixon, Mark
    Clark, Emma
    Humphrey, Kathryn
    Hutchings, Martin
    Trney, Marek
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (24): : 2220 - 2231
  • [7] Total Cost of Care in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
    Gatwood, Justin
    Masaquel, Anthony
    Ross, Ryan
    Sheinson, Danny
    Hossain, Farah
    Li, Jia
    James, Cameron
    Fox, David
    BLOOD, 2022, 140 : 7906 - 7907
  • [8] Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2
    Kim, Won-Seog
    Kim, Tae Min
    Cho, Seok-Goo
    Jarque, Isidro
    Iskierka-Jazdzewska, Elzbieta
    Poon, Michelle Limei
    Prince, H. Miles
    Oh, Sung Yong
    Lim, Francesca
    Carpio, Cecilia
    Tran-Der Tan
    Ayyappan, Sabarish
    Gutierrez, Antonio
    Li, Jingjin
    Ufkin, Melanie
    Zhu, Min
    Chaudhry, Aafia
    Mohamed, Hesham
    Ambati, Srikanth R.
    Walewski, Jan
    BLOOD, 2022, 140 : 1070 - 1071
  • [9] Glofitamab plus Polatuzumab Vedotin demonstrates durable responses and a manageable safety profile in patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
    Dietrich, S.
    Hutchings, M.
    Avigdor, A.
    Sureda, A.
    Terol, M. J.
    Bosch, F.
    Corradini, P.
    Larsen, Stauffer T.
    Dominguez, Rueda A.
    Skarbnik, A.
    Jorgensen, J.
    Goldschmidt, N.
    Gurion, R.
    Zinzani, P. L.
    Pinto, A.
    Cordoba, R.
    Bottos, A.
    Huang, Z.
    Simko, S.
    Relf, J.
    de L'Etang, Filezac A.
    Sellam, G.
    Gritti, G.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 209 - 209
  • [10] Final Analysis of the Phase 2 ELM-2 Study: Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
    Ayyappan, Sabarish
    Kim, Won Seog
    Kim, Tae Min
    Walewski, Jan
    Cho, Seok-Goo
    Jarque, Isidro
    Iskierka-Jazdzewska, Elzbieta
    Poon, Michelle
    Oh, Sung Yong
    Lim, Francesca Lorraine Wei Inng
    Carpio, Cecilia
    Tan, Tran-Der
    Gutierrez, Antonio
    Zhang, Huilai
    Cao, Junning
    Zhang, Mingzhi
    Tessoulin, Benoit
    Li, Jingjin
    Ufkin, Melanie
    Shariff, Saleem
    Chi, Lei
    Chaudhry, Aafia
    Mohamed, Hesham
    Ambati, Srikanth
    Prince, H. Miles
    BLOOD, 2023, 142
12345